Integra LifeSciences (IART) Stock: Buy, Sell, or Hold?
IART - Integra LifeSciences Holdings
$11.84
-1.49 (-11.18%)
▼
5d:
-10.13%
30d:
-26.09%
90d:
-36.21%
HOLD
MODERATE Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Oct 21, 2026
0d
Get Alerted When IART Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: IART shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: IART shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$17.59
Based on 4.9% avg growth
INTRINSIC VALUE TODAY
$10.92
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 5.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: IART is currently trading at $11.84, which is considered oversold relative to its 30-day fair value range of $13.17 to $15.95. From a valuation perspective, the stock is trading at a discount (Forward PE: 4.7) compared to its historical average (5.5). Remarkably, the market is currently pricing in an annual earnings decline of 5.1% over the next few years. This pessimistic expectation contrasts with the company's recent 0.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, IART is in a downtrend. The price is currently testing key support at $11.57. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 11.2% recently.
Market Sentiment: The stock scores a mixed 51/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $18.00 (+52.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, IART is in a downtrend. The price is currently testing key support at $11.57. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 11.2% recently.
Market Sentiment: The stock scores a mixed 51/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $18.00 (+52.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$13.17 -
$15.95
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
74.8%
Protect Your Profits
Holding IART? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (51/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-11.2%)
- BULLISH: Trading 52.0% below Wall St target ($18.00)
- NEUTRAL: Bottoming setup forming (51/100) — watch for confirmation
- CAUTION: 5-day price weakness (-10.1%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$13.17 -
$15.95
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$11.57
Resistance Level
$14.28
Current Trend
Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
4.70
Wall Street Target
$18.00
(+52.0%)
Revenue Growth (YoY)
0.8%
Earnings Growth (YoY)
0.4%
Profit Margin
-0.4%
Valuation Discount vs History
-5.1% cheaper
PE vs Historical
4.7 vs 5.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.1%
(market-implied from PE analysis)
1-Year Target
$11.24
(-5%)
2-Year Target
$10.66
(-10%)
3-Year Target
$10.12
(-15%)
3-Yr Target (if PE normalizes)
(PE: 5→6)
$11.84
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 5.8%)
$59.26
(+401%)
Base:
(SPY PE: 4.7, Growth: 5.8%)
$14.03
(+19%)
Bear:
(PE: 4.0, Growth: 5.8%)
$11.92
(+1%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 4.7 to 5.5
Stabilization Target:
$13.85
(+17.0%)
PE Expansion Potential:
+17.0%
Share & Embed Analysis
Last updated: October 21, 2026 7:08 PM ET
Data refreshes hourly during market hours. Next update: 8:08 PM
Data refreshes hourly during market hours. Next update: 8:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IART showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
31 analysts |
$59 | 50 HOLD |
|
SYK
Stryker Corporation |
STRONG BUY
29 analysts |
$363 | 37 SELL |
|
MDT
Medtronic PLC |
BUY
29 analysts |
$105 | 43 HOLD |
|
AXGN
Axogen Inc |
STRONG BUY
12 analysts |
$54 | 75 BUY |
|
TNDM
Tandem Diabetes Care Inc |
BUY
25 analysts |
$28 | 54 HOLD |
Advanced IART Option Strategies
Professional options setups generated by AI based on today's IART price and gamma walls.
